Publications

MARÍA CONCEPCIÓN GARCÍA GARCÍA publications

29 results

2026

  1. Neurodegeneration and the endocannabinoid system: Toward the development of cannabinoid-based therapies for Parkinson's disease, amyotrophic lateral sclerosis and spinocerebellar ataxias

    Handbook of Behavioral Neuroscience (Elsevier B.V.), pp. 425-450

2025

  1. Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (−) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives

    European Journal of Medicinal Chemistry Reports, Vol. 14

2022

  1. Editorial: Cannabinoids as potential treatment for neurological diseases

    Frontiers in Neuroscience

2021

  1. Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  2. Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease

    Molecules, Vol. 26, Núm. 11

  3. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice

    Molecular and Cellular Neuroscience, Vol. 110

  4. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

2020

  1. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

    Neurobiology of Disease, Vol. 141

2019

  1. Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease

    Molecules, Vol. 24, Núm. 15

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

    Methods in Enzymology (Academic Press Inc.), pp. 175-198

2016

  1. Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia

    British Journal of Pharmacology, pp. 2069-2079

  2. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 64, pp. 200-208

  3. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice

    Pharmacological Research, Vol. 110, pp. 181-192

2015

  1. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson's disease

    Neuroscience Letters, Vol. 587, pp. 1-4

2014

  1. Neurodegenerative disorders other than multiple sclerosis

    Handbook of Cannabis (Oxford University Press), pp. 505-525

2013

  1. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?

    British Journal of Clinical Pharmacology, Vol. 75, Núm. 2, pp. 323-333

  2. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors

    Neuropharmacology, Vol. 75, pp. 155-163

2011

  1. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson's disease

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1495-1506

2010

  1. Different Susceptibility to the Parkinson's Toxin MPTP in Mice Lacking the Redox Master Regulator Nrf2 or Its Target Gene Heme Oxygenase-1

    PLoS ONE, Vol. 5, Núm. 7, pp. e11838